Avalyn Pharma Inc.
AVLN
Sync financial data to generate a health grade for this company.
Analytical Summary
Review the statement evidence below to form a view on AVLN.
6-Year Financial Trajectory
QuarterlyStatement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | Q2 FY2026 Jun 30, 2026 10-Q ↗ | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q2 FY2025 Jun 30, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-Q ↗ |
|---|---|---|---|---|---|---|
| EPS Growth YoY (%) |
94.4%
Excellent
Excellent
Year-over-year change in earnings per share
Optimal:
> 10%
|
65.5%
Excellent
Excellent
Year-over-year change in earnings per share
Optimal:
> 10%
|
— | — | — | — |
| Net Income Growth YoY (%) |
-53.5%
Weak
Weak
Year-over-year change in net income |
-53.5%
Weak
Weak
Year-over-year change in net income |
— | — | — | — |
| FCF Growth YoY (%) |
95.1%
Excellent
Excellent
Year-over-year change in free cash flow |
64.8%
Excellent
Excellent
Year-over-year change in free cash flow |
— | — | — | — |
| Metric | Q2 FY2026 Jun 30, 2026 10-Q ↗ | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q2 FY2025 Jun 30, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-Q ↗ |
|---|---|---|---|---|---|---|
| FCF / Net Income (x) |
0.98x
Caution
↓
Caution
Declining
Free cash flow relative to reported net income
Optimal:
> 1x
|
1.12x
Fair
→
Fair
Stable
Free cash flow relative to reported net income
Optimal:
> 1x
|
— |
1.18x
Fair
Fair
Free cash flow relative to reported net income
Optimal:
> 1x
|
1.10x
Fair
Fair
Free cash flow relative to reported net income
Optimal:
> 1x
|
— |
| Metric | Q2 FY2026 Jun 30, 2026 10-Q ↗ | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q2 FY2025 Jun 30, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-Q ↗ |
|---|---|---|---|---|---|---|
| Return on Invested Capital (%) |
-6.0%
Weak
↓
Weak
Declining
Return earned on debt + equity capital invested
Optimal:
> 10%
|
8.8%
Fair
↑
Fair
Improving
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— |
8.9%
Fair
Fair
Return earned on debt + equity capital invested
Optimal:
> 10%
|
7.7%
Fair
Fair
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— |
| Return on Capital (%) (%) |
-7.4%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
-20.6%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
— | — | — | — |
| Return on Common Equity (%) (%) |
-6.7%
Weak
↓
Weak
Declining
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-145%)
|
10.2%
Fair
↑
Fair
Improving
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-32%)
|
— |
9.0%
Caution
Caution
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-40%)
|
9.1%
Caution
Caution
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-39%)
|
— |
| Metric | Q2 FY2026 Jun 30, 2026 10-Q ↗ | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q2 FY2025 Jun 30, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-Q ↗ |
|---|---|---|---|---|---|---|
| Debt to Equity (x) |
0.04x
Excellent
↑
Excellent
Improving
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Below avg (-94%)
|
-0.06x
Excellent
Excellent
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Below avg (-109%)
|
0.00x
Excellent
Excellent
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Below avg (-100%)
|
— | — | — |
| Net Debt (USD) | $-249.40M | $-77.50M | $-52.31M | — | — | — |
| Debt / EBITDA (x) |
-0.47x
Excellent
Excellent
Debt relative to earnings before interest, taxes, depreciation
Optimal:
< 2x
|
-0.53x
Excellent
Excellent
Debt relative to earnings before interest, taxes, depreciation
Optimal:
< 2x
|
— | — | — | — |
| Metric | Q2 FY2026 Jun 30, 2026 10-Q ↗ | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q2 FY2025 Jun 30, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-Q ↗ |
|---|---|---|---|---|---|---|
| Working Capital (USD) | $347.18M | $118.20M | $129.47M | — | — | — |
| LT Debt (USD) | $14.80M | $14.81M | $0.00 | — | — | — |
| Total Equity (USD) | $398.35M | $-264.25M | $-238.66M | $-194.39M | $-191.57M | $-174.52M |
| Metric | Q2 FY2026 Jun 30, 2026 10-Q ↗ | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q2 FY2025 Jun 30, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-Q ↗ |
|---|---|---|---|---|---|---|
| Depreciation Expense (USD) | $110.00K | $63.00K | — | $9.00K | $10.00K | — |
| Net Income, GAAP (USD) | $-26.87M | $-26.87M | — | $-17.50M | $-17.50M | — |
| Operating Cash Flow (USD) | $-26.08M | $-29.89M | — | $-20.70M | $-19.27M | — |
Secondary lens
Benchmark Lens
Compare AVLN against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare AVLN against peers after checking the statement evidence.
Compare AVLN with peers
Stack AVLN against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced yesterday